BACKGROUND: Tyrosine kinase inhibitors (TKI) such as sorafenib have substantially improved the prognosis of metastatic renal cell carcinoma (mRCC) patients, but long-term remissions have only been reached with immunotherapy. Sequencing or combining TKI treatment with immunotherapy may represent an attractive therapeutic concept. However, in vitro data have shown that TKI may not only affect tumour cells, but also inhibit signalling in immune effector cells. Therefore, we asked whether sorafenib had an influence on peripheral immune effector cells in a cohort of 35 mRCC patients receiving sorafenib treatment. METHODS: Peripheral blood (pB) samples were analysed at baseline and after 8 weeks of treatment. IL-10 and TGF-ß mRNA levels were quantified by RT-PCR; regulatory T cell (Treg) counts and intracellular cytokine responses (TNF-α, IFN-γ, IL-10 and TGF-ß) of mononuclear cell subsets were determined by flow cytometry after in vitro stimulation with PMA/ionomycin. RESULTS: Sorafenib did not alter the elevated TGF-ß and IL-10 mRNA levels or elevated frequencies of IL-10 and TGF-ß producing monocytes and had no influence on type 1 cytokine responses in pB. CD4+CD25(high) FOXP3+/CD3+ T cells, likely representing Treg cells, decreased during sorafenib therapy. CONCLUSIONS: In vivo, sorafenib treatment was associated with a decrease in frequency of Treg cells without influencing the function of peripheral immune effector cells. Therefore, although sorafenib did not convert the immunosuppressive phenotype associated with mRCC, it seemed to be a possible candidate for combination with immunotherapy.
BACKGROUND: Tyrosine kinase inhibitors (TKI) such as sorafenib have substantially improved the prognosis of metastatic renal cell carcinoma (mRCC) patients, but long-term remissions have only been reached with immunotherapy. Sequencing or combining TKI treatment with immunotherapy may represent an attractive therapeutic concept. However, in vitro data have shown that TKI may not only affect tumour cells, but also inhibit signalling in immune effector cells. Therefore, we asked whether sorafenib had an influence on peripheral immune effector cells in a cohort of 35 mRCC patients receiving sorafenib treatment. METHODS: Peripheral blood (pB) samples were analysed at baseline and after 8 weeks of treatment. IL-10 and TGF-ß mRNA levels were quantified by RT-PCR; regulatory T cell (Treg) counts and intracellular cytokine responses (TNF-α, IFN-γ, IL-10 and TGF-ß) of mononuclear cell subsets were determined by flow cytometry after in vitro stimulation with PMA/ionomycin. RESULTS:Sorafenib did not alter the elevated TGF-ß and IL-10 mRNA levels or elevated frequencies of IL-10 and TGF-ß producing monocytes and had no influence on type 1 cytokine responses in pB. CD4+CD25(high) FOXP3+/CD3+ T cells, likely representing Treg cells, decreased during sorafenib therapy. CONCLUSIONS: In vivo, sorafenib treatment was associated with a decrease in frequency of Treg cells without influencing the function of peripheral immune effector cells. Therefore, although sorafenib did not convert the immunosuppressive phenotype associated with mRCC, it seemed to be a possible candidate for combination with immunotherapy.
Authors: Melek M E Sunay; Jeremy B Foote; James M Leatherman; Justin P Edwards; Todd D Armstrong; Christopher J Nirschl; Jessica Hicks; Leisha A Emens Journal: Int Immunopharmacol Date: 2017-03-07 Impact factor: 4.932
Authors: Roniel Cabrera; Miguel Ararat; Yiling Xu; Todd Brusko; Clive Wasserfall; Mark A Atkinson; Lung Ji Chang; Chen Liu; David R Nelson Journal: Cancer Immunol Immunother Date: 2012-12-07 Impact factor: 6.968
Authors: Xiangxuan Zhao; Changhai Tian; William M Puszyk; Olorunseun O Ogunwobi; Mengde Cao; Ton Wang; Roniel Cabrera; David R Nelson; Chen Liu Journal: Lab Invest Date: 2012-10-29 Impact factor: 5.662
Authors: C Tanchot; M Terme; H Pere; T Tran; N Benhamouda; M Strioga; C Banissi; L Galluzzi; G Kroemer; E Tartour Journal: Cancer Microenviron Date: 2012-10-27
Authors: Sara E Martin del Campo; Kala M Levine; Bethany L Mundy-Bosse; Valerie P Grignol; Ene T Fairchild; Amanda R Campbell; Prashant Trikha; Thomas A Mace; Bonnie K Paul; Alena Cristina Jaime-Ramirez; Joseph Markowitz; Sri Vidya Kondadasula; Kristan D Guenterberg; Susan McClory; Volodymyr I Karpa; Xueliang Pan; Thomas E Olencki; J Paul Monk; Amir Mortazavi; Susheela Tridandapani; Gregory B Lesinski; John C Byrd; Michael A Caligiuri; Manisha H Shah; William E Carson Journal: J Immunol Date: 2015-08-03 Impact factor: 5.422